Follow us on Google News
In a major crackdown on counterfeit pharmaceuticals, the Delhi Police Crime Branch has busted a fake medicine manufacturing unit operating out of Loni in Ghaziabad. The police seized a large consignment of counterfeit drugs and arrested two accused, including the factory owner.
Initial investigation revealed that the factory was producing spurious medicines for skin-related ailments, which were being supplied across Delhi, Haryana, Punjab, Rajasthan, and Uttar Pradesh, forming a wide distribution network in northern India.
https://the420.in/fcrf-certified-grc-professional-program-governance-risk-compliance-training-india/
Operation Originated from Sadar Bazar Raid
According to officials, the operation began after a raid in Delhi’s Sadar Bazar. Acting on a tip-off, the Crime Branch found that fake medicines were being sold in bulk through local traders. During the raid, two suspects were apprehended, and hundreds of packets of counterfeit drugs were recovered.
On interrogation, the accused disclosed that the medicines were being manufactured at a secret factory in Loni, Ghaziabad. Following this revelation, a Crime Branch team, with support from the local administration, raided the factory premises and seized raw materials, packaging machines, labels, and finished drugs ready for distribution.
Huge Seizure and Key Mastermind Held
During the factory search, police found thousands of strips of counterfeit medicines, along with chemical drums, sealing machines, and packaging material imitating reputed pharmaceutical brands.
Officials confirmed that one of the arrested individuals is the factory owner and mastermind, while the second handled the distribution network. The accused allegedly replicated popular pharmaceutical brand labels to circulate their fake products across the region.
Police said the chemical substances used in these medicines posed serious health hazards, as none of them met safety or regulatory standards.
Network Spread Across North India
Investigators have found that the counterfeit medicine racket had links spreading across Delhi, Uttar Pradesh, Haryana, Punjab, and Uttarakhand. The accused supplied medicines at undercut rates to local chemists and wholesale distributors, making detection difficult.
A senior officer said, “We have sent the seized samples to the Drugs Control Department laboratory for analysis. Preliminary tests show that the products did not comply with any recognized manufacturing standards or licenses.”
A Threat to Public Health
Experts warn that such counterfeit medicines can cause serious skin infections, allergic reactions, and long-term health complications.
Pharmaceutical analysts have called it not just a case of fraud, but a direct threat to public health and consumer safety.
Delhi Police stated that the accused have been booked under Sections 318 (Cheating to obtain property fraudulently), 336 (Forgery), and 337 (Making forged documents) of the Bharatiya Nyaya Sanhita (BNS) 2023, along with relevant provisions of the Drugs and Cosmetics Act, 1940.
Investigators are also tracing the suppliers, financers, and logistic links associated with the racket.
Crackdown on Counterfeit Drug Syndicates
Authorities believe this operation is part of a larger organized syndicate involved in the manufacture and distribution of fake medicines using fraudulent licenses and duplicate labeling.
The Delhi Police Crime Branch is now coordinating with the Central Drugs Standard Control Organization (CDSCO) to dismantle the entire network. Sources said that more raids are planned in the coming weeks across Delhi-NCR and neighboring states to eliminate similar illegal operations.
The Ghaziabad raid marks one of the most significant recent breakthroughs by the Delhi Police in tackling health-related crimes.
The case underlines how counterfeit drug manufacturing is not only a criminal offense but also a public health emergency capable of endangering countless lives.
Police officials stated that further arrests are likely as the investigation progresses, and those found complicit in the network will face strict legal action under the Bharatiya Nyaya Sanhita and drug safety laws.
